Nadia Khan, MD
- Request Appointment
- Clinical Locations
- About
- Education and Training
- Patient Stories
- Publications
- Ratings
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Secondary Location
Fox Chase–Temple University Hospital Bone Marrow Transplant Program
Temple University Hospital – Jeanes Campus
Patient Care Center, Fifth Floor
7600 Central Avenue
Philadelphia, PA 19111
Assistant Professor, Department of Hematology/Oncology
NCCN, Hodgkin Lymphoma Panel Member
Research Program
Treatment Philosophy
Educational Background
- Fellow, Hematology-Oncology, Georgetown University, Washington, DC, 2010-2013
- Resident, Internal Medicine, Temple University, Philadelphia, PA, 2008-2010
- MD, Lewis Katz School of Medicine, Temple University, Philadelphia, PA
Memberships
- National Comprehensive Cancer Network (NCCN)
- Hodgkin Lymphoma Panel
Chase Chait
Chase Chait
I started out 2021 as an active, healthy 26-year-old transgender man. I was an avid hiker. I was engaged, and I was on my way to a promotion at my job. But by early 2022, I was also a cancer survivor living with HIV.
Tierra Ryan
Tierra Ryan
At 31, Tierra Ryan was a young professional woman, working as a pharmacist and a medical writer for a large pharmaceutical company, when she was shocked to learn she was diagnosed with Hodgkin's lymphoma. Fox Chase Cancer Center was one of two hospitals her doctor recommended. Tierra underwent chemotherapy and radiation therapy at Fox Chase, and in November 2014 was placed on surveillance because her cancer was in remission. Today, she still works in the pharmaceutical industry, but as a medical science liaison focusing on oncology. "I’m truly thankful to the doctors and staff at Fox Chase because they saved my life," Tierra said. "Because of them, I have a long life ahead of me."
Selected Publications
Single-Route CNS Prophylaxis for Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes From 21 US Academic Institutions
Orellana-Noia VM, Reed D, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins MP, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers AA, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law JY, Karmali R, Shah HR, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko JM, Cohen JB, Portell CA
Blood 2021 Sep 27; [Epub ahead of print]
Venetoclax With Dose-Adjusted EPOCH-R as Initial Therapy for Patients With Aggressive B-Cell Lymphoma: A Single-Arm, Multicentre, Phase 1 Study
Rutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N, Joyce R, Maddocks K, Ali-Shaw T, Senese S, Yuan Y, Westin J, Leonard JP
Lancet Haematol 2021 Nov;8(11):e818-e827
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Nowakowski GS, Hong F, Scott DW, Macon WR, King RL, Habermann TM, Wagner-Johnston N, Casulo C, Wade JL, Nagargoje GG, Reynolds CM, Cohen JB, Khan N, Amengual JE, Richards KL, Little RF, Leonard JP, Friedberg JW, Kostakoglu L, Kahl BS, Witzig TE
J Clin Oncol 2021 Apr 20;39(12):1329-1338
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Alderuccio JP, Olszewski AJ, Evens AM, Collins GP, Danilov AV, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim SH, Vaca R, Wei C, Sundaram S, Reddy N, Dalla Pria A, D'Angelo C, Farooq U, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy M, Rabinovich E, Post FA, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, Epperla N, Caimi P, Smith SE, Kamdar M, Venugopal P, Feldman TA, Rector D, Smith SD, Stadnik A, Portell C,A Lin Y, Naik S, Montoto S, Lossos IS, Cwynarski K .
Blood Adv 2021 Jul; 5 (14): 2852–2862.
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
Zayac AS Evens AM Danilov A Smith SD Jagadeesh D Leslie LA Wei C Kim SH Naik S Sundaram S Reddy N Farooq U Kenkre VP Epperla N Blum KA, Khan N Singh D Alderuccio JP Godara A Yazdy MS Diefenbach C Rabinovich E Varma G Karmali R Shao Y Trabolsi A Burkart M Martin P Stettner S Chauhan A Choi YK Straker-Edwards A Klein A Churnetski MC Boughan KM Berg S Haverkos BM Orellana-Noia VM D'Angelo C Bond DA Maliske SM Vaca R Magarelli G Sperling A Gordon MJ David KA Savani M Caimi P Kamdar M Lunning MA Palmisiano N Venugopal P Portell CA Bachanova V Phillips T Lossos IS Olszewski AJ .
Haematol. 2021 Jul;106(7):1932-1942.
Burkitt Lymphoma International Prognostic Index.
Olszewski AJ Jakobsen LH Collins GP Cwynarski K Bachanova V Blum KA, Boughan KM Bower M Dalla Pria A Danilov A David KA Diefenbach C Ellin F Epperla N Farooq U Feldman TA Gerrie AS Jagadeesh D Kamdar M Karmali R Kassam S Kenkre VP Khan N Kim SH Klein AK Lossos IS Lunning MA Martin P Martinez-Calle N Montoto S Naik S Palmisiano N Peace D Phillips EH Phillips TJ Portell CA Reddy N Santarsieri A Sarraf Yazdy M Smeland KB Smith SE Smith SD Sundaram S Zayac AS Zhang XY Zhu C Cheah CY El-Galaly TC Evens AM .
J Clin Oncol. 2021 Apr 1;39(10):1129-1138.
NCCN Guidelines(R) Insights: B-Cell Lymphomas, Version 5.2021
Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H
J Natl Compr Canc Netw 2021 Nov;19(11):1218-1230
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology
Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar H
J Natl Compr Canc Netw 2020 Feb;18(2):185-217
Abstracts
Phase II Study of Venetoclax in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma As Front Line Therapy (PrECOG 0403). Craig A Portell, Opeyemi Jegede, Nina D Wagner-Johnston, Grzegorz S Nowakowski, Christopher D Fletcher, Jonathon B Cohen, Kevin A David, Nadia Khan, Lori J Rosenstein, Brad S Kahl.
Blood 2021; 138 (Supplement 1): 814. doi: https://doi.org/10.1182/blood-2021-145217
Abstract CT133: Targeting BCL-2 and MCL-1 overcomes treatment resistance in relapsed and refractory non-Hodgkin lymphoma: Pre-clinical rationale and results from an open-label phase 1b study.
Dhara N. Amin, Rajat Bannerji, Raghuveer Singh Mali, Jason Oeh, Eva Lin, Anuradha Zindal, MaryAnn Go, Shang-Fan Yu, Maxwell Krem, Chris Arthur, Uwe Hahn, Anna M. Johnston, Vinit G. Karur, Nadia Khan, Paula Marlton, Tycel Phillips, Giuseppe Gritti, John F. Seymour, Monica Tani, Sam Yuen Yuen, Scott Martin, Matthew T. Chang, Christopher M. Rose, Victoria C. Pham, Elizabeth A. Lasater, Andrew G. Polson, YiMeng Chang, Jamie Hirata, Lisa Musick, Deepak Sampath, Christopher R. Flowers and Ingrid E. Wertz.
AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. doi: 10.1158/1538-7445.AM2020-CT133 Published August 2020
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Secondary Location
Fox Chase–Temple University Hospital Bone Marrow Transplant Program
Temple University Hospital – Jeanes Campus
Patient Care Center, Fifth Floor
7600 Central Avenue
Philadelphia, PA 19111
Assistant Professor, Department of Hematology/Oncology
NCCN, Hodgkin Lymphoma Panel Member
Research Program
Treatment Philosophy
Education
Educational Background
- Fellow, Hematology-Oncology, Georgetown University, Washington, DC, 2010-2013
- Resident, Internal Medicine, Temple University, Philadelphia, PA, 2008-2010
- MD, Lewis Katz School of Medicine, Temple University, Philadelphia, PA
Memberships
- National Comprehensive Cancer Network (NCCN)
- Hodgkin Lymphoma Panel
Publications
Selected Publications
Single-Route CNS Prophylaxis for Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes From 21 US Academic Institutions
Orellana-Noia VM, Reed D, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins MP, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers AA, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law JY, Karmali R, Shah HR, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko JM, Cohen JB, Portell CA
Blood 2021 Sep 27; [Epub ahead of print]
Venetoclax With Dose-Adjusted EPOCH-R as Initial Therapy for Patients With Aggressive B-Cell Lymphoma: A Single-Arm, Multicentre, Phase 1 Study
Rutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N, Joyce R, Maddocks K, Ali-Shaw T, Senese S, Yuan Y, Westin J, Leonard JP
Lancet Haematol 2021 Nov;8(11):e818-e827
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Nowakowski GS, Hong F, Scott DW, Macon WR, King RL, Habermann TM, Wagner-Johnston N, Casulo C, Wade JL, Nagargoje GG, Reynolds CM, Cohen JB, Khan N, Amengual JE, Richards KL, Little RF, Leonard JP, Friedberg JW, Kostakoglu L, Kahl BS, Witzig TE
J Clin Oncol 2021 Apr 20;39(12):1329-1338
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Alderuccio JP, Olszewski AJ, Evens AM, Collins GP, Danilov AV, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim SH, Vaca R, Wei C, Sundaram S, Reddy N, Dalla Pria A, D'Angelo C, Farooq U, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy M, Rabinovich E, Post FA, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, Epperla N, Caimi P, Smith SE, Kamdar M, Venugopal P, Feldman TA, Rector D, Smith SD, Stadnik A, Portell C,A Lin Y, Naik S, Montoto S, Lossos IS, Cwynarski K .
Blood Adv 2021 Jul; 5 (14): 2852–2862.
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
Zayac AS Evens AM Danilov A Smith SD Jagadeesh D Leslie LA Wei C Kim SH Naik S Sundaram S Reddy N Farooq U Kenkre VP Epperla N Blum KA, Khan N Singh D Alderuccio JP Godara A Yazdy MS Diefenbach C Rabinovich E Varma G Karmali R Shao Y Trabolsi A Burkart M Martin P Stettner S Chauhan A Choi YK Straker-Edwards A Klein A Churnetski MC Boughan KM Berg S Haverkos BM Orellana-Noia VM D'Angelo C Bond DA Maliske SM Vaca R Magarelli G Sperling A Gordon MJ David KA Savani M Caimi P Kamdar M Lunning MA Palmisiano N Venugopal P Portell CA Bachanova V Phillips T Lossos IS Olszewski AJ .
Haematol. 2021 Jul;106(7):1932-1942.
Burkitt Lymphoma International Prognostic Index.
Olszewski AJ Jakobsen LH Collins GP Cwynarski K Bachanova V Blum KA, Boughan KM Bower M Dalla Pria A Danilov A David KA Diefenbach C Ellin F Epperla N Farooq U Feldman TA Gerrie AS Jagadeesh D Kamdar M Karmali R Kassam S Kenkre VP Khan N Kim SH Klein AK Lossos IS Lunning MA Martin P Martinez-Calle N Montoto S Naik S Palmisiano N Peace D Phillips EH Phillips TJ Portell CA Reddy N Santarsieri A Sarraf Yazdy M Smeland KB Smith SE Smith SD Sundaram S Zayac AS Zhang XY Zhu C Cheah CY El-Galaly TC Evens AM .
J Clin Oncol. 2021 Apr 1;39(10):1129-1138.
NCCN Guidelines(R) Insights: B-Cell Lymphomas, Version 5.2021
Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H
J Natl Compr Canc Netw 2021 Nov;19(11):1218-1230
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology
Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar H
J Natl Compr Canc Netw 2020 Feb;18(2):185-217
Abstracts
Phase II Study of Venetoclax in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma As Front Line Therapy (PrECOG 0403). Craig A Portell, Opeyemi Jegede, Nina D Wagner-Johnston, Grzegorz S Nowakowski, Christopher D Fletcher, Jonathon B Cohen, Kevin A David, Nadia Khan, Lori J Rosenstein, Brad S Kahl.
Blood 2021; 138 (Supplement 1): 814. doi: https://doi.org/10.1182/blood-2021-145217
Abstract CT133: Targeting BCL-2 and MCL-1 overcomes treatment resistance in relapsed and refractory non-Hodgkin lymphoma: Pre-clinical rationale and results from an open-label phase 1b study.
Dhara N. Amin, Rajat Bannerji, Raghuveer Singh Mali, Jason Oeh, Eva Lin, Anuradha Zindal, MaryAnn Go, Shang-Fan Yu, Maxwell Krem, Chris Arthur, Uwe Hahn, Anna M. Johnston, Vinit G. Karur, Nadia Khan, Paula Marlton, Tycel Phillips, Giuseppe Gritti, John F. Seymour, Monica Tani, Sam Yuen Yuen, Scott Martin, Matthew T. Chang, Christopher M. Rose, Victoria C. Pham, Elizabeth A. Lasater, Andrew G. Polson, YiMeng Chang, Jamie Hirata, Lisa Musick, Deepak Sampath, Christopher R. Flowers and Ingrid E. Wertz.
AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. doi: 10.1158/1538-7445.AM2020-CT133 Published August 2020
20 PATIENT COMMENTS
-
5.0
March 22, 2022
Dr. Khan and her team are caring and responsive. She always spends a lot of time in caring for me.
-
5.0
March 21, 2022
Dr. Nadia Khan is an EXCELLENT doctor for my needs/concerns.
-
5.0
March 05, 2022
I received professional, courteous service.
-
No Star Ratings Available
February 23, 2022
Dr. Khan is very knowledgeable physicians and good person. She took time during appointment to hear all my concerns and ordered several tests to make sure I feel comfortable about my condition.
-
5.0
January 29, 2022
My experience with Dr. Nadia Kahn is always the best. She answers honestly to my questions and I always feel satisfied when I leave her office.
-
5.0
December 20, 2021
I'm glad that Fox Chase is close to my home, so I can get the best care possible.
-
5.0
December 16, 2021
I would give Dr. Khan much higher than a 10 if I could. Excellent compassionate care.
-
5.0
December 15, 2021
Dr. Khan is a wonderful doctor. She goes above and beyond to ensure that her patients needs are met. [...]
-
5.0
October 22, 2021
I always look forward to my follow-up appts. with Dr. Khan. She takes her time with me and my wife. Answers all our questions concerns very helpful & kind!!
-
5.0
August 14, 2021
Dr Kahn and staff including [...] ( chemo nurse) were very good in helping me get through the day
-
5.0
August 13, 2021
Everyone is always so kind and helpful at Fox Chase Cancer Center. My doctor, Dr Khan is wonderful
-
5.0
August 06, 2021
This was a wonderful 1st visit for me with Dr. Khan. She is a top notch educated doctor in her field. She explained my condition to me, and answered all of my questions with the utmost care and concern, and spent time with me. She educated me about my cancer, and made me feel comforted and that I am & will be well cared for by her. I left feeling that I had made the best choice possible by picking Dr Khan as my oncologist, and Fox Chase Cancer Center as my cancer hospital. I am a totally satisfied patient.
-
No Star Ratings Available
July 28, 2021
Dr Kahn explained everything but used a great deal of medical terminology that was hard to understand
-
5.0
July 24, 2021
Dr. Khan is a wonderful doctor. She sets the bar high for other providers. She takes extra time with each patient and explains things in a way that I can understand. She is always available and returns calls quickly if I have a question. I am so blessed to have her as my doctor and as a part of my medical team.
-
5.0
July 24, 2021
Dr. Khan has been my oncologist for almost 3 years. She is the most caring, thoughtful, positive and knowledgeable doctor I see. She goes above and beyond to attend to my care and I am extremely comfortable with the amazing care she has provided me. Dr. Khan saved my life and I am so grateful for her and my entire hematology team. They are the best ever!
-
5.0
May 24, 2021
The care I've received from Dr. Khan and her staff has always been exceptional. I love and appreciate everyone.
-
5.0
May 17, 2021
Dr Kahn is knowledgeable and so caring. we are so fortunate to have her as our Dr
-
No Star Ratings Available
April 21, 2021
My whole experience with Fox Chase & Dr. Khan was wonderful, comfortable.
-
5.0
February 14, 2021
The best care
-
5.0
December 31, 2020
[...] I am very satisfied in all respects.
LOAD MORE